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SUMMARY 
ALG raised against lymphoblasts grown in pure culture for many generations 
contained anti platelet activity. The thromboagglutinins could be completely 
removed by absorption with lymphoblasts, indicating that they had been raised to 
antigens shared by lymphoblasts and platelets. Anti-spleen ALG possessed levels of 
such anti-platelet antibodies but in substantially higher titres, because an additional 
contribution was made by contaminating thrombocytes in the immunizing in-
jectate. By chromatographic separation and immunoelectrophoretic analysis of the 
eluate from platelet-antibody complexes generated during the absorption of anti-
spleen ALG with thrombocytes, the thromboagglutinins were shown to reside 
almost exclusively (97,7%) in the area of the IgA fraction. The direct Coombs' 
test, reacting platelets from patients receiving equine anti-spleen ALG with 
guinea-pig antisera against normal horse serum, showed a highly significant, but 
not invariable correlation with clinical platelet depression, which was not, however, 
clearly related to the thromboagglutinin titre of the ALG being administered. 
INTRODUCTION 
Thrombocytopenia often has been observed in recipients of organ transplants under 
treatment with differing immunosuppressive regimens. More than one factor has been 
indicted, including simple bone marrow depression (Starzl, 1964). In addition, previous 
reports from our department showed a relationship between thrombocytopenia and graft 
platelet entrapment during acute (Groth et al., 1968) and hyperacute rejection (Giles et aI., 
1970; Simpson et aI., 1970; Starzl et ai., 1970). Sequestration of thrombocytes in grafts can 
also occur by a non-immunologic pathway, particularly in livers (Hutchison et al., 1968). 
Correspondence: Dr T. E. Starzl, Veterans Administration Hospital, 1055 Clermont Street, Denver, 
Colorado 80220, U.S.A. 
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It is equally well known that horse antilymphocyte serum (ALS) can cause thrombo-
cytopenia (Starzl et al., 1967; Ono et at., 1969; Starzl, 1969). Work in our laboratory (Starzl, 
1969; Starzl et al., 1969) and by PichI mayer et al. (1968) and James et al. (1970) suggested 
that some platelet killing could be expected even with ALS raised with pure collections of 
lymphocytes because of antigens shared between platelets and lymphocytes. Nevertheless, 
Najarian et al. (1969, 1970) have claimed that ALS raised in horses against cultured human 
lymphoblasts (grown by Dr G. Moore, Roswell Park Memorial Institute, Buffalo, New 
York) did not produce thrombocytopenia in any of their patients. 
In the present investigation, the anti platelet activity of horse ALS raised by splenic 
lymphocytes was compared to that in equine ALS raised against cultured lymphoblasts 
(grown by Dr G. Moore). Antiplatelet activity was found in both products and charac-
terized for its immunochemical nature, specificity, and cross-reactivity. In addition, studies 
were performed in thirty-six kidney recipients treated with horse antispleen ALS in order 
to show the mechanism of the induced thrombocytopenia. The degree of platelet depression 
was shown to correlate with the coating of patients' platelets with horse IgA (positive 
direct Coombs' test.) 
METHODS 
Preparation and testing of ALS 
The antigen. The cell suspensions were injected in horses subcutaneously over 3-6 
months. Four horses received fourteen to thirty inoculations with splenic lymphocytes 
(Iwasaki et al., 1967); the other two were given seventeen to twenty injections over 2-3 
months of cultured lymphoblasts that had been growing for more than 1000 generations 
in the laboratory of Dr G. Moore, Buffalo, New York. 
Titres. Antibodies raised in the two different kinds of horses were measured in the raw 
horse serum at various phases of processing and in the refined antilymphocyte globulin 
(ALG). Haemagglutinins, leukoagglutinins and lymphocytotoxins were measured by 
techniques previously reported from our laboratory (Iwasaki et al., 1967; Kashiwagi et al., 
1970). The thromboagglutinins were determined by the method described by Kashiwagi 
et al. (1970), incubating for 6 hr without agitation. 
Absorption procedures. The crude anti splenic (and the anti lymphoblast) ALS for clinical 
use were absorbed (Iwasaki et al., 1967; Kashiwagi et al., 1969) with pooled fresh human 
red blood cells and with human platelets to remove excessive haem agglutinins and thrombo-
agglutinins respectively. The ALG was then prepared by ammonium sulphate precipitation 
(Iwasaki et al., 1967). 
Other absorption studies 
Antilymphoblast ALS from two different horses was diluted five times and then absorbed 
four to six times (37°C for 2 hr and 4°C for 12 hr) with an equal volume of human red 
cells that were purified eight times by differential centrifugation. In addition, diluted ALS 
was absorbed two or three times under the same conditions with three times the volume 
of packed lymphoblasts. Haemagglutinin, leukoagglutinin, thromboagglutinin and 
lymphocytotoxin titres were measured before and after these procedures. 
The nature of the antiplatelet antibody 
After the platelet absorption mentioned previously, the agglutinated platelets were 
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assumed to have complexed with specific antibody. The platelets were suspended in normal 
saline and submitted to differential centrifugation six to ten times to remove contaminating 
red and white blood cells. 
Elution of antibody. The thromboagglutinins were eluted by the method of Stelos (1967). 
After suspending 3 g of agglutinated platelets in 20 ml glycine-HCI buffer (pH 2·3, 0·15 M) 
at 4°C for 20 min while stirring, the supernatant containing antiplatelet antibody was 
removed by centrifugation at 7000 g for 30 min and the pH adjusted to 8·0 with saturated 
NaOH solution. Precipitation was then carried out with ammonium sulphate (50% sat.). 
The precipitate was dissolved in distilled water and dialysed against tap water and normal 
saline solution for chromatography as described below. 
DEAE-cellulose column chromatography. Gradient chromatography was carried out in a 
28 x 4 cm column containing activated Whatman DE-32 cellulose (H. Reeve Angel & 
Co. Ltd, London, England) (Sober & Peterson, 1958). The samples and cellulose were 
equilibrated with the initial sodium phosphate buffer (pH 8'0, 0·005 M). Elution was at a 
rate of 20 ml/hr. After the first peak was completely eluted, the acidity and molality of 
the buffer were gradually increased to pH 5'0, 0·2 M. The protein concentration of each 
tube was measured with a Hitachi-Perkins spectrophotometer at a wave length of 280 m,u. 
The thromboagglutinin and haemagglutinin titres of each tube were then determined. 
Immunoelectrophoresis. A representative tube from each of the three major protein 
peaks defined by chromatography was analysed by Scheidegger's (1955) method. The 
sample was placed in the centre well of a 0·1 % agar gel plate and electrophoresed at a 
potential difference of 5 V/cm for 90 min. The two troughs were then filled with guinea-
pig anti-horse IgG and IgA antisera (raised in our laboratory by immunization with a 
purified IgA fraction; Oriol, Binaghi & Boussac-Aron., 1968), which are said by Oriol et al. 
(1968) to react only with the heavy chains of equine immunoglobulin molecules. Incubation 
was for 48 hr at 20D C (Amemiya et al., 1970). 
Coombs' test of patients' platelets 
The platelets of thirty-six kidney recipients were studied for coating antibodies after 
treatment postoperatively with antisplenic ALS for 11-93 (mean 30·0± 12 SD) days. Five 
ml of blood were mixed with 0'5 ml of 5% EDTA in saline and centrifuged at 1200 g for 
60 sec to separate the platelet-rich plasma. The latter was washed once in 10 volumes of 
Eagle's basal medium containing one-tenth volume EDTA-saline solution, and recentri-
fuged (1000 g for 5 min). The thrombocyte plug was resuspended in EDTA-Eagle's solution 
to a cell concentration of about 500,OOO/mm3 • Red and white blood cell contamination 
was 0·10 ±M·MS~~ and 0'98±1'15%, respectively. 
Preparation of Coombs' reagent. Rabbit antiserum to normal horse serum (Hyland 
Corporation, Los Angeles, California) was completely absorbed with human 0, A and B 
red blood cells. After absorption, the antiserum was sufficiently diluted with buffered 
saline solution to eliminate all positive reactions with normal human thrombocytes. 
Usually the dilution ratio was sixteen times the original antiserum concentration. Finally, 
the antiserum was further diluted with the same solution so that it gave a precipitation 
titre of 1 : 500 when reacted by Ouchterlony's antigen dilution method with normal horse 
serum, the initial protein concentration of which was standardized at 1 g%. 
The direct Coombs' test. Using a microtitre plate, the Coombs' reagent was serially 
diluted from I: 1 to I: 64 with phosphate buffered saline solution (pH 7'1, 0·15 M). An 
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equal volume (0'025 ml) of the platelet suspension was added to each well and the tray 
incubated for 6 hr at 20°C following which the configuration in each well was read with 
the magnifying reflector. 
RESULTS 
Antibodies in the ALS 
Antispleen ALS. During immunization, extremely high tit res of lymphocytotoxins and 
leukoagglutinins were raised. Coincidentally, haemagglutinin titres increased to 1: 4096 
and thromboagglutinins to 1: 512 (Fig. 1). As mentioned earlier, these last two antibodies 
were absorbed out before globulin extraction. 
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FIG. 1. Immunizing schedules and the resulting lymphocytotoxin, leukoagglutinin, haemag-
glutinin, and thromboagglutinin titres for two horses inoculated with human lymphoblasts 
and spleen cells, respectively. The lymphoblast dose is given as the weight of the cell suspension 
in grams (l g equals approximately 109 lymphoblasts, of which usually less than 30% were 
viable by the Erythrosin-B dye exclusion test). Only the lymphocytes in the spleen cell sus-
pension were counted; of these, 30-70% were thought to be viable. The titres are expressed 
as the reciprocal of the greatest dilution of serum giving a positive reaction by that test. 
Antilymphoblast ALS. The immunizing dose schedule in terms of cell number and the 
timing of injections was comparable to that with the 'spleen' horse. The animal responded 
with the highest rises in the leukoagglutinins and lymphocytotoxins. However, there were 
also significant increases in the haemagglutinins and thromboagglutinins to 1: 512 and to 
1: 64, respectively (Fig. 1). 
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The effect of absorption upon antilymphoblast ALS 
The raw antilymphoblast ALS obtained from the two different horses was diluted with 
buffered saline solution to the titres and protein contents shown in Table 1. Multiple 
absorptions with red blood cells completely removed the haemagglutinins but had no 
significant effect upon leukoagglutinins, lymphocytotoxins or thromboagglutinins. 
In contrast (Table 1), absorption two or three times with packed lymphoblasts removed 
not only the lymphocytotoxins and leukoagglutinins but most or all of the thrombo-
agglutinins and haemagglutinins as well. The absorption of the anti-platelet and anti-red 
cell antibodies could in no sense be ascribed to accidental contamination by platelets and/or 
red cells since the lymphoblasts had been in a blood free cell culture for many generations. 
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FIG. 2. Chromatographic and immunoelectrophoretic analyses of thromboagglutinins eluted 
from platelet-antibody complexes formed during the absorption of horse antispleen ALS by 
human thrombocytes. Two protein peaks contained anti platelet activity. The larger was 
identified by immunoelectrophoresis with guinea-pig antisera as equine JgA; the smaller was 
IgG. 
The nature of the antiplatelet antibody 
After chromatography of the eluate from the platelet-antibody complexes, anti platelet 
activity was seen in two of the three protein peaks; the largest, which was estimated to 
contain 97'7% of the total, was IgA (Fig. 2) insofar as could be determined with guinea-pig 
antisera. The smaller antibody peak was IgG. The third protein peak which did not contain 
antibody was highly acid and probably represented breakdown derivatives of the platelets. 
Clinical studies and Coombs' tests 
The results with chromatography prompted the use of a rabbit serum raised against 
whole horse serum as the Coombs' reagent since the common practice of using an anti-IgG 
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serum would have detected only a tiny fraction (less than 3%) of the total antiplatelet 
activity. 
Thrombocytopenia versus a positive Coombs' test. There was a highly significant corre-
lation (P < 0·01) between the development of a positive Coombs' test and thrombocytopenia 
(Table 2). However (Fig. 3), it was often noticed that a Coombs' test became positive 
some days or weeks before the maximum depression of the platelet count. Conversely, 
recovery of platelets was often delayed for some time after discontinuance of ALG therapy 
and even sometimes for several days after the Coombs' test became negative (Fig. 3). 
Thrombocytopenia versus antiplatelet titre of ALG. There was no significant difference in 
platelet depression between those patients receiving ALG with a very low anti thrombocyte 
titre and those patients whose ALG had titres greater than 1 : 256. Similarly, these titres 
did not correlate with the presence of a positive Coombs' test (Table 3). 
TABLE 2. Chi-square analysis of the incidence of platelet depression 
versus the results of the Coombs' test in thirty-six recipients of 
renal homografts treated with antispleen ALG 
Platelet depression-r 
Present 
Absent 
Total 
Coombs' test* 
Positive Negative 
8 3 
2 23 
10 26 
X2 = 12·89 >6·63 (P < 0'01) 
Total 
11 
25 
36 
* The criteria for inclusion in the Coombs' positive group were 
positive reactions on two successive occasions or frequent (30% or 
more) positive Coombs' tests during the period of ALG admini-
stration. 
t Platelet depression was defined as a thrombocyte count on two 
consecutive days of less than 150,000/mm3 (or less than the pre-
ALG control if the latter were below 150,OOO/mm3). 
DISCUSSION 
Antiplatelet actlVlty in ALS and ALG has been recognized to be a significant hazard 
since the earliest clinical trials with these agents (Starzl et al., 1967; Starzl, 1969). From 
the beginning, two distinct aetiologic factors seemed likely. One which was emphasized 
from our laboratory (Starzl, 1969; Ono et al., 1969) and by Woiwod et al. (1970) was that 
an antibody could accidentally be raised against platelets as well as against erythrocytes by 
the inadvertent inclusion of thrombocytes and red cells in the cell suspensions used for 
immunization. Ways of reducing this kind of contamination in preparing spleens and 
other tissues for injection have been described by Townsend et al. (1969) but Woiwod et al. 
(1970) have underscored the difficulties of getting rid of all platelets. 
The second possible factor which was supported by several authors (Pichlmayer et al., 
1968; James et al., 1970; Starzl ,1969; Starzl et al., 1969) but not by others (Najarian et aI., 
1969, 1970) was that platelets and red cells had certain antigens in common with lymphoid 
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FIG. 3. The course of a recipient of a cadaveric renal homograft whose thrombocytopenia was 
associated with Coombs' positive reactivity. Note that the Coombs' test turned positive 
before depression of the platelet count could be documented. After stopping the antispleen 
ALG, the Coombs' tests rapidly became negative. The platelet count, however, did not return 
to normal for about 3 weeks, but then remained above 150,OOO/mm3 even though treatment 
with a new batch (shaded blocks) of ALG was instituted. 
TABLE 3. Incidence of thrombocyte depression and positive Coombs' tests in fifteen patients receiving 
ALG with low thromboagglutinin titres and in seven recipients given high thromboagglutinin titre ALG 
Thromboagglutin in No. of Thrombocyte Positive Coombs' 
titre of ALG patients depression* reaction * 
~ I: 32 15 4 EOSDS/~F 5 (33'3:%;) 
? I : 256 7 2 (28·6:%;) I (14'3:%;) 
* See Table 2 for criteria. 
cells and that, as a consequence, purely antilymphocyte antibodies cross-reacted with the 
other formed elements. Incontrovertible proof for this later hypothesis awaited the use of 
cultured lymphoblasts for immunizing antigen, since this approach ruled out for the first 
time all possibility of extraneous red cells or platelets in the injectates. Under these con-
ditions, in the present study antilymphoblast ALS was shown to contain haemagglutinins 
and thromboagglutinins. 
These findings were hardly surprising in view of the evidence that platelets share antigens 
with a variety of other cells (Gilboa-Garber & Nelken, 1961; Shulman, Moor-Jankowsky 
& Hiller, 1965; Hanna & Nelken, 1968). However, the 'sharing' is undoubtedly variable 
in different cell membranes. For example, in the present study Iymphoblasts injected in 
horses elicited unwanted haemagglutinins and thromboagglutinins in addition to the 
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desired leukoagglutinins and lymphocytotoxins. All of these antibodies were absorbed with 
Iymphoblasts. In contrast, red cells were effective absorbers solely against haemagglutinins. 
Past work has showed that absorption with platelets can be carried out without reducing 
Iymphocytotoxin titres (Starzl, 1969; Starzl et al., 1969). Thus, complete representation of 
all the antigens in the system being tested could be found only in the lymphoblasts. 
At the moment, there seems no reason to suspect that thromboagglutinins raised with 
platelets are inherently either more or less thrombocytopenic than those resulting from 
shared lymphocyte antigens. It seems more likely that any in vivo effect would represent 
roughly the sum of both these factors. Immunochemically, two distinct kinds of thrombo-
agglutinins could not be identified in antispleen ALS. Almost all anti platelet identity 
seemed to be in IgA, as was previously claimed by Kashiwagi et al. (1970). 
With the use of the direct Coombs' test, an idea was obtained of the regularity with 
which IgA attached to circulating platelets and contributed to thrombocytopenia. There 
was a highly significant correlation between positive Coombs' tests and platelet depression. 
However, the association was not invariable and in addition there were some patients with 
thrombocytopenia who had negative Coombs' tests. Moreover, the strength of the anti-
platelet titre in the ALG did not correlate either with the incidence of positive Coombs' 
tests or the severity of thrombocytopenia, as might have been predicted by the data of 
Kamoun & Hamburger (1970). Consequently, it seems likely that the other factors men-
tioned in the introduction of this article played an important role in many of the post-
transplantation thrombocytopenias. These could include the pre-existing state of the 
recipient haematopoietic system, bone marrow depression post-transplantation by immuno-
suppressants, platelet sequestration in the graft because of rejection or mechanical trauma, 
and other less well defined processes that could contribute either to accelerated platelet 
destruction or to retarded platelet production. 
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